Biosimilars 2008, a two day conference conducted exclusively to air the issues associated with biosimilars, would be held at George Washington University, Washington DC, from September 22 to 23. Organised under the aegis of Scherago International, this year Biosimilars conference would air issues associated with the proposed legislation for biotech medicines currently under consideration with the US Congress to provide the authority for the food and drug administration (FDA) to regulate biosimilars.

This two day conference will bring experts from the industry and academy sector together to discuss the latest developments in biosimilars regulations, clinical assessment, manufacturing processes and pricing and reimbursement. Through a series of presentations and interactive discussions, participants are expected to gain new insight and share hands-on experiences in the latest trends and practices in the development of biosimilars.

"Biosimilars 2008 is expected to attract pharma and biotechnology players from the USA, Europe, Japan, India, Singapore, China, Israel and other countries with biotech and generic biotech organisations. The conference would feature sessions on legislative and policy, legal/patent, economic and financial and regulatory and technical aspects of biosimilars. The event would also feature panel session at the conclusion of each session for conference attendees to ask questions and interact with the speakers," said the organisers.

The global development of biosimilars is now recognised to be a critical part of the future of biotechnology, as the pharma, legal and payor/patient communities consider the legal, scientific, technical, financial and economic impacts.

The conference would offer a golden opportunity for the participants to hear from, and interact with leading professionals from government, non-governmental organisations and the private sector.

"The conference will cover the main areas and issues of interest and concern to the innovator and generic pharma industry and public legislative, legal and patent/intellectual property, economic/financial, regulatory, scientific and standards issues, experience of the EU procedures, public sector concerns and health care industry interests," noted the organisers.